Plus Therapeutics(US:PSTV) Globenewswire·2025-07-15 11:30Core Insights - Plus Therapeutics is set to present the final results of its ReSPECT-LM clinical trial at the SNO/ASCO CNS Metastases Conference, highlighting the safety and efficacy of its treatment for leptomeningeal metastases [1][2] - The company will also host an educational symposium focusing on advancements in managing leptomeningeal metastases, featuring presentations from leading neuro-oncologists [3] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, specializing in targeted radiotherapeutics for central nervous system cancers [8] - The company is advancing a pipeline of product candidates, particularly in the areas of leptomeningeal metastases and recurrent glioblastoma, utilizing image-guided local beta radiation and targeted drug delivery [8] Product Information - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy developed by Plus Therapeutics, designed to deliver targeted high-dose radiation to CNS tumors [6] - REYOBIQ is currently being evaluated in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, with significant funding support from various institutions [6] Industry Context - Leptomeningeal metastases are a severe complication of advanced cancer, occurring in approximately 5% of metastatic cancer patients, with limited effective treatment options available [5] - The median survival for patients with leptomeningeal metastases is typically between 2 to 6 months, underscoring the urgent need for novel therapies [5]